<DOC>
	<DOCNO>NCT01271517</DOCNO>
	<brief_summary>Hypothesis : Basal insulin analogs continuous 24-hour delivery insulin improve glycemic control first year treatment children/adolescents type 1 diabetes mellitus ( T1DM ) preserve endogenous insulin production close normal balance GH-IGF-axis . This randomized , open-label , parallel-group trial 120 child , 7 - 17 year age , newly diagnose T1DM . The investigator investigate whether use long-acting basal insulin analog Lantus ( Glargine ) Levemir ( Detemir ) first year treatment result improved glycemic control ( HbA1c ) compare Insulatard ( NPH insulin ) give meal insulin therapy regimen rapid act Novorapid ( insulin aspart ) . The investigator explore possible mechanisms action determine remain endogenous insulin production change GH-IGF-axis . The investigator also assess change body composition evaluate quality life treatment arm .</brief_summary>
	<brief_title>Basal Analog Study - Comparison Lantus Levemir With NPH Insulin From T1DM Diagnosis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Diagnosis diabetes novel insulin therapy Age 7 17 year Informed consent Moderate severe ketoacidosis ( pH &lt; 7.2 and/or standard bicarbonate &lt; 10 mmol/l ) Suspected nontype 1 IA2 GAD65 : allantibody negative Celiac disease chronic disease Hypothyroidism , well control Syndromes Previous anorexia nervosa Neuropsychiatric disease Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Basal insulin</keyword>
	<keyword>long act insulin analog</keyword>
	<keyword>metabolic control</keyword>
	<keyword>HbA1c</keyword>
	<keyword>C-peptide</keyword>
	<keyword>IGF-I</keyword>
	<keyword>GH</keyword>
	<keyword>IGFBP</keyword>
</DOC>